Spain’s Almirall has announced strategic plans at the 43rd JP Morgan Healthcare Conference based on expected double-digit growth within the dermatological area for Almirall’s psoriasis and atopic dermatitis franchises.
The company’s dermatology business is driven by Ebglyss (lebrikizumab) and Ilumetri (tildrakizumab). The company further reveals that these medications are anticipated to lead to over EUR800m ($820.66m) in annual peak sales. Moreover, the global sales are expected to increase as the medications are launched in key markets, and Almirall expects Ebglyss to land in a dozen countries by 2025, twice as many as in 2024.
Go deeper with GlobalData
For the Catalan company, medical dermatology is considered the driving force, and in 2023, this area represented 52% of its income with a turnover of EUR465.2m ($477.36m). Nevertheless, the company revealed that it has seen an increase in its turnover in Europe, while in the USÂ it has recorded a decline. Eli Lilly has the exclusive rights to develop and commercialize Ebglyss globally, apart from Europe, while Almirall has licensed the rights to commercialise Ebglyss in Europe.
While Ebglyss has gained regulatory approval in the EU, Canada, South Korea, and Japan, it has struggled to secure positive reimbursement status across Europe, due to competition in the atopic dermatitis market. Additionally, it has been found that Ebglyss has a similar therapeutic value to Sanofi and Regeneron’s rival treatment Dupixent (dupilumab) in the same indication, as a treatment for adult and adolescent patients with moderate to severe atopic dermatitis.
In a similar manner, Spain’s Ministry of Health (MoH) proposed that Pfizer’s atopic dermatitis treatment Cibinqo (abrocitinib) is equivalent to Almirall’s Ebglyss. This news was a surprise to Almirall because the MoH had previously stated that their treatment had more variables of use than Pfizer’s, and as a result, Ebglyss entered the Spanish market at a higher price.
To date, GlobalData’s pricing and reimbursement service reveals that only five EU member states have awarded general reimbursement status to Ebglyss, including the Netherlands (December 2024), Italy (November 2024), the Czech Republic (June/September 2024), Germany (December 2023), and Spain (reimbursement in hospitals only). Nevertheless, Almirall claims that medical dermatology continues to be a sector with significant unmet needs based on the severe patient impact of a wide range of dermatological diseases, uncontrolled patients with chronic diseases, increasing numbers of diagnoses, and the transition of more patients to advanced treatments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGlobalData forecasts that global sales for Ebglyss are expected to increase, and the drug will reach blockbuster status in 2027 at $1.12bn. For Ilumetri, GlobalData forecasts that the drug’s sales will continue to increase annually, reaching $691m in 2027.
This article is produced as part of GlobalData’s Price Intelligence (POLI) service, the world’s leading resource for global pharmaceutical pricing, HTA and market access intelligence integrated with the broader epidemiology, disease, clinical trials and manufacturing expertise of GlobalData’s Pharmaceutical Intelligence Center. Our unparalleled team of in-house experts monitor P&R policy developments, outcomes and data analytics around the world every day to give our clients the edge by providing critical early warning signals and insights. For a demo or further information, please contact us here.
